Adrienne H. Brouwers

Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer

Eli Dijkers, Thijs H. Oude Munnink, Jos G. W. Kosterink et al. · Clinical Pharmacology & Therapeutics · 2010 · 807 citations

Medicine, Nuclear Medicine, Oncology +17

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub–de Hooge et al. · Nature Medicine · 2018 · 734 citations · Full text

Medicine, Oncology, Pharmacology +17

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana et al. · Annals of Oncology · 2015 · 348 citations · Full text

Medicine, Molecular Medicine, Oncology +17

In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft

Wouter B. Nagengast, Elisabeth G.E. de Vries, Geke A.P. Hospers et al. · Journal of Nuclear Medicine · 2007 · 314 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Improved Staging of Patients With Carcinoid and Islet Cell Tumors With ¹⁸F-Dihydroxy-Phenyl-Alanine and ¹¹C-5-Hydroxy-Tryptophan Positron Emission Tomography

Klaas Pieter Koopmans, Oliver Neels, Ido P. Kema et al. · Journal of Clinical Oncology · 2008 · 238 citations · Full text

Medicine, Nuclear Medicine, Oncology +17